Komori
Ishihara Chemical (4462) · RiskRestated

Risk of Reduced Sales and Business Disruption Due to COVID-19

First written in FY2020. 5 of 12 entries say "Restated". Latest entry: FY2026.

12entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021-Q3 – FY2022-Q3MitigatedFY2023-Q2 – FY2024-Q1ReframedFY20252020: 320202021: 320212022: 220222023: 220232024: 020242025: 120252026: 12026
Same theme, other companies
Risk of COVID-19 impacts on business activities, supply chains, demand and financial performanceA theme 1257 companies write about · 1269 as a headwind · 6 as a tailwind

The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1283 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「The Group conducts sales activities in Japan and overseas. If facilities are damaged or people are harmed by natural disasters such as major earthquakes and typhoons, or by infectious diseases including novel viruses, the Group's results may be affected.」

    The company continues to use wording that broadens the scope from a description limited to COVID-19 to a business continuity risk including natural disasters, novel viruses and other factors.
  2. FY2025ReframedAnnual report

    「The Group conducts sales activities in Japan and overseas. If facilities are damaged or people are harmed by natural disasters such as major earthquakes and typhoons, or by infectious diseases including novel viruses, the Group's results may be affected.」

    The wording has been broadened from a description focused on COVID-19 to a business continuity risk encompassing natural disasters and infectious diseases including novel viruses.
  3. FY2024-Q1MitigatedAnnual report

    「During the consolidated cumulative first quarter under review, the Japanese economy continued on a gradual recovery path as the negative impact of COVID-19 on economic activity eased. However, the outlook remained uncertain due to the effects of rising prices and the slowdown in overseas economies.」

    The company states that the negative impact of COVID-19 on the economy has eased and that the economy is on a gradual recovery path, indicating that the manifestation of the pandemic-related risks of lower sales and business continuity issues has weakened.
  4. FY2023-Q3MitigatedAnnual report

    「During the consolidated cumulative third quarter under review, the Japanese economy recovered gradually as economic and social activity normalized under the concept of living with COVID-19. However, the outlook remained uncertain due to the prolonged situation in Ukraine, global inflation and monetary tightening.」

    Under the concept of living with COVID-19, the company notes the normalization of economic and social activity and an economic recovery, while the impact of the pandemic-related economic stagnation has become less pronounced than in the previous period. Meanwhile, uncertainty caused by other external factors continues.
  5. FY2023-Q2MitigatedAnnual report

    「During the six-month consolidated cumulative period, there were signs of a recovery in the Japanese economy as economic and social activity moved toward normalization under the concept of living with COVID-19. However, the outlook remains uncertain due to the impact of the situation in Ukraine, soaring crude oil and raw material prices on domestic and overseas economies, and the effects of yen depreciation.」

    The company notes the normalization of economic and social activity and signs of a recovery, while its description of the economic stagnation caused by COVID-19 has become less pronounced than in the previous period. Meanwhile, uncertainty related to the situation in Ukraine, crude oil and raw material prices, and yen depreciation continues.
  6. FY2022-Q3RestatedAnnual report

    「During the nine-month consolidated cumulative period, the Japanese economy remained in a difficult situation due to the impact of COVID-19. In addition, the emergence of new COVID-19 variants means that the outlook for the end of the pandemic remains uncertain.」

    The company continues to identify the impact of COVID-19, including the emergence of new variants, and uncertainty over when the pandemic will end as risks.
  7. FY2022-Q2RestatedAnnual report

    「Although COVID-19 vaccinations are progressing, the outlook for the end of the pandemic remains uncertain.」

    While noting progress in vaccinations, the company continues to state that the outlook for the end of the pandemic remains uncertain and to disclose the risk of lower sales and business continuity issues caused by the pandemic.
  8. FY2022-Q1RestatedAnnual report

    「During the three-month consolidated cumulative period, the Japanese economy remained in a difficult situation due to the impact of COVID-19. With the state of emergency declared repeatedly, the outlook for the end of the pandemic remains uncertain.」

    The company continues to identify the difficult economic conditions caused by COVID-19 and uncertainty over when the pandemic will end as risks.
  9. FY2021-Q3RestatedAnnual report

    「During the nine-month consolidated cumulative period, the Japanese economy remained in a difficult situation as the global spread of COVID-19 caused the economy to cool, despite signs of a recovery in personal consumption and exports.」

    The company states that the economic deterioration caused by COVID-19 has continued. However, operating income, ordinary income and net income for the nine-month cumulative period exceeded the same period of the previous year, so the effects differ from those seen through the previous quarter.
  10. FY2021-Q2MaterialisedAnnual report

    「As a result, performance for the first half of the fiscal year under review was as follows: net sales of ¥8,135 million, down 1.8% year on year; operating profit of ¥592 million, down 31.2%; ordinary profit of ¥662 million, down 26.3%; and net income attributable to owners of the parent of ¥513 million, down 19.6%.」

    As a result of the deterioration in market conditions caused by COVID-19, the company reported year-on-year declines in net sales, operating income, ordinary income, and quarterly net income attributable to owners of the parent.
  11. FY2021-Q1MaterialisedAnnual report

    「Under these circumstances, the Group worked to expand the market for high-value-added products by implementing working from home and distributed work arrangements as measures against COVID-19 and advancing sales activities using web conferencing systems, but was affected by the deterioration of market conditions caused by COVID-19.」

    The deterioration in market conditions caused by COVID-19 has occurred in practice, appearing in the company's overall results as declines in ordinary income and net income, and by segment as reduced production of automotive and smartphone-related products, among others.
  12. FY2020First statedAnnual report

    「COVID-19 is expected to reduce sales in each segment, and the extent of its impact may vary depending on when the pandemic ends.」

    The company separately disclosed COVID-19 for the first time as a new significant risk that could reduce sales across all segments. For accounting purposes, it assumed that the impact would continue through September 2020, but did not provide a specific amount of sales lost during the fiscal year.
Moved together

"Business expansion through the development of new products, technologies and markets" moved the same way as this thread, in the same document, in 3 of its 12 moves.

333222★123456
  1. ★This thread
  2. 1Business expansion through the development of new products, technologies and markets3×
  3. 2Risk of Price Declines and Market Volatility Relating to Securities Held3×
  4. 3Verification of the Rationale for Holding Strategic Shareholdings and Maintaining and Strengthening Business Relationships3×
  5. 4Enhancing corporate value by improving ordinary profit, ROE and EPS2×
  6. 5Diversification of Production Locations and Expansion of Production Capacity2×
  7. 6Priority Allocation of Retained Earnings to Research and Development, New Businesses and New Technologies2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Ishihara Chemical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.